Clinical trial of treatment for ‘surfer’s eye’ - University of the Sunshine Coast, Queensland, Australia

Accessibility links

USC News

Clinical trial of treatment for ‘surfer’s eye’

11 Mar 2019

A condition called pterygium – also known as “surfer’s eye” – is now in the sights of USC’s Clinical Trials Centre, which has joined an international trial of a non-surgical treatment for the ailment.

The centre will work with Associate Professor Leo Hartley of H2 Vision Centres at Chancellor Park to assess an investigational medicine that aims to reduce the eye redness associated with the condition.

Associate Professor Hartley said people with pterygium experienced thin growths of clear tissue with redness, due to small blood vessels that start at the corner of the eye and grow towards the centre of the cornea. If left untreated, it can lead to blindness.

This potential new treatment aims to reduce the growth of these small blood vessels.

“As part of the clinical trial, patients will be randomly selected to receive an eye drop containing either the new drug, or a lubricant similar to artificial tears. Both treatments will be given three times a day for 28 days,” he said.

“This potential new treatment may turn out to be a game-changer in the management of pterygium, for which the only current treatment is surgery. We are looking forward to seeing the results.”

USC Clinical Trials Centre Director Lucas Litewka said the Sunshine Coast was well suited to this trial, due to its beautiful sunny beaches and outdoor lifestyle.

“While the Sunshine Coast is all about sun, sand and surf, too much exposure to these things without adequate eye protection can be damaging to your eyes,” he said.

Mr Litewka said the condition was not restricted to surfers, and could affect anyone who experienced plenty of UV exposure, especially in dusty areas.

People interested in participating can go to USC’s Clinical Trials Centre or call (07) 5456 3797. This study has been approved by Bellberry Human Research Ethics Committee. Pictured is the USC CTC's Senior Clinical Research Coordinator Jessica Baird, right, showing the product to a patient.

Related articles

Professor Jeanine Young, left, and PhD student Rebecca Shipstone
Disadvantage and adversity behind high sudden infant death rate
17 Feb

Queensland’s first large-scale study of all sudden infant deaths to date has identified key factors contributing to the state’s persistently high annual death rate of babies.

Clinical trial of experimental new treatment for chronic plaque psoriasis
28 Jan

USC Clinical Trials is about to begin a study of an experimental new treatment for mild to moderate chronic plaque psoriasis, a common skin condition.

Malaria clinical trial
USC Clinical Trials seeks healthy volunteers for malaria study
5 Jan

USC Clinical Trials has partnered with the QIMR Berghofer Medical Research Institute in Brisbane to investigate whether an approved anti-malarial drug can be used more extensively to counter malaria – a disease that claims more than 400,000 lives worldwide each year.

Contact the USC media team

Name Position Email Phone
Terry Walsh Manager, Media and Messaging twalsh@usc.edu.au +61 7 5430 1160
Janelle Kirkland Media Relations Coordinator jkirklan@usc.edu.au +61 7 5459 4553
Clare McKay Media Relations Officer (Regional) cmckay@usc.edu.au +61 7 5456 5669

Search results for

Recent news